Ann: Immutep granted Chinese patent for its LAG-3 candidate Efti, page-33

China patent is a big deal.
If there is anywhere in the world patent protection is needed its China.
This also provides EOC with some comfort/ confidence to press on with efti/chemo combi trial.
Huge potential market in China. If P2 data is compelling could be approved by NMPA (FDA equivalent) relatively quickly as MBC is unmet need and increasing around 4% PA. This is partly due to Urbanisation (mega cities) and single child legislation:
-The health burden of cancer is increasing in China, with more than 1·6 million people being diagnosed and 1·2 million people dying of the disease each year. As in most other countries, breast cancer is now the most common cancer in Chinese women; cases in China account for 12·2% of all newly diagnosed breast cancers and 9·6% of all deaths from breast cancer worldwide. China's proportional contribution to global rates is increasing rapidly because of the population's rising socioeconomic status and unique reproductive patterns.